Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 4/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPY1R | P25929 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29964333 | 0.84 | CCR5 (0.52) | CCR5SLC6A4SLC6A2SLC6A3KMT2A | |
| SCHEMBL16294005 | 0.81 | PTGDR2 (0.40) | CCR5KMT2APTGDR2ALDH1A1RAB9A | |
| SCHEMBL16294286 | 0.78 | CCR5 (0.41) | CCR5KMT2APTGDR2RAB9A | |
| SCHEMBL17152708 | 0.78 | PTGDR2 (0.38) | CCR5KMT2APTGDR2ALDH1A1RAB9A | |
| SCHEMBL16293949 | 0.77 | CSNK2A1 (0.40) | CCR5KMT2APTGDR2ALDH1A1RAB9A | |
| SCHEMBL29888844 | 0.76 | SLC6A4 (0.56) | CCR5SLC6A4SLC6A2SLC6A3KMT2A | |
| SCHEMBL3696560 | 0.76 | SLC6A4 (0.56) | CCR5SLC6A4SLC6A2SLC6A3KMT2A | |
| SCHEMBL29888798 | 0.76 | CCR5 (0.57) | CCR5SLC6A4SLC6A2SLC6A3KMT2A | |
| SCHEMBL17705278 | 0.76 | LMNA (0.41) | CCR5SLC6A4KMT2AALDH1A1RAB9A | |
| SCHEMBL7766037 | 0.75 | AAK1 (0.46) | SLC6A4ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-10-17 | — | — | US | disclosed |
| WO-2022226668-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | CMPK1, WNK1, AAK1 | CCR5 3103/4885SLC6A4 3317/4885SLC6A2 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.